Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignancy and autoimmunity.

Sasha Bernatsky1, Rosalind Ramsey-Goldman, Ann Clarke

  • 1Division of Clinical Epidemiology, Montreal General Hospital, Quebec, Canada. sasha.bernatsky@elf.mcgill.ca

Current Opinion in Rheumatology
|February 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vitro Fertilization is Essential Healthcare for Patients With Rheumatic Disease.

ACR open rheumatology·2026
Same author

Bias due to interval censored outcomes in a study of flare risk after hydroxychloroquine taper/cessation in systemic lupus erythematosus.

Journal of clinical epidemiology·2026
Same author

C4b-binding protein as an antigenic target in the pathogenesis of antiphosphatidylethanolamine autoantibodies.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A highly prevalent lupus risk haplotype increases IRF7-dependent induction of IFN-α, enhancing antiviral defense and exacerbating autoimmunity.

medRxiv : the preprint server for health sciences·2026
Same author

Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality.

Annals of the rheumatic diseases·2025
Same author

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Autoimmune rheumatic diseases are linked to an increased cancer risk, particularly lymphoma and lung cancer in rheumatoid arthritis. Further research is needed for scleroderma and cancer associations.

Area of Science:

  • Rheumatology
  • Oncology
  • Immunology

Background:

  • The link between autoimmune diseases and cancer risk has been a growing area of research.
  • Previous studies suggest an elevated risk of certain cancers in patients with autoimmune rheumatic diseases.

Purpose of the Study:

  • To review recent publications on the association between cancer and autoimmune rheumatic diseases.
  • To focus on rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, and scleroderma/systemic sclerosis.

Main Methods:

  • Literature review of recent publications.
  • Analysis of reported cancer risks in specific autoimmune rheumatic diseases.

Main Results:

  • Rheumatoid arthritis patients show an increased risk of lymphoma and potentially lung cancer.

Related Experiment Videos

  • Sjogren's syndrome is associated with non-Hodgkin's lymphomas, with potential underlying mechanisms being investigated.
  • Systemic lupus erythematosus carries an increased risk, primarily for lymphoma; scleroderma shows less clear associations due to imprecise data.

    • Conclusions:

    • Recent literature confirms associations between inflammatory arthritis, Sjogren's syndrome, systemic lupus erythematosus, and scleroderma with specific cancers.
    • Continued investigation into autoimmune rheumatic diseases and malignancy is warranted for better understanding of both conditions.